April 26, 2017Open Access
View Full PaperSpironolactone Metabolites in TOPCAT — New Insights into Regional Variation
Key Result
Spironolactone metabolite canrenone was undetectable in 30% of TOPCAT participants from Russia compared with only 3% from the United States and Canada.
Structured PICO
Does adherence to spironolactone vary by geographic region among participants in the TOPCAT trial?
P
Population
Subgroup of TOPCAT participants assigned to spironolactone
I
Intervention
Spironolactone
O
Outcome
Adherence assessed by spironolactone metabolite canrenone levelssurrogate
There was significant regional variation in adherence to spironolactone in the TOPCAT trial, with substantially higher rates of non-adherence in Russia compared to North America, which may explain the trial's regional outcome differences.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
In a subgroup of TOPCAT participants assigned to spironolactone, the spironolactone metabolite canrenone was measured to assess adherence. Canrenone levels were undetectable in 30% of participants from Russia, as compared with only 3% from the United States and Canada.